Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02467270
Title Ponatinib in Patients With Resistant Chronic Phase Chronic Myeloid Leukemia (CML) to Characterize the Efficacy and Safety of a Range of Doses
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Ariad Pharmaceuticals
Indications

chronic myeloid leukemia

Therapies

Ponatinib

Age Groups: adult
Covered Countries USA | ITA | FRA | ESP | DEU | CAN


No variant requirements are available.